Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.64 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550866 | 1.00 | ALDH1A1 (0.64) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL31065280 | 0.98 | ALDH1A1 (0.61) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL16719254 | 0.98 | ALDH1A1 (0.61) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL16626048 | 0.90 | ALDH1A1 (0.52) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL16626047 | 0.90 | ALDH1A1 (0.52) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL15504697 | 0.90 | ALDH1A1 (0.52) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL15504742 | 0.90 | ALDH1A1 (0.52) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL396943 | 0.87 | ALDH1A1 (0.54) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL15504691 | 0.87 | ALDH1A1 (0.48) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL15504724 | 0.86 | ALOX15 (0.46) | ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464243-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL SCIENT IND RES (IN) | 2025-02-12 | — | — | EP | claimed |
| US-11274081-B2 | Process for the synthesis of ivacaftor | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-03-15 | — | — | US | claimed |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-15 | — | — | US | claimed |
| EP-3464243-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | Council of Scientific and Industrial Research (IN) | 2019-04-10 | — | — | EP | claimed |
| CN-105884628-B | The preparation method of 2,4- di-t-butyl -5- amino phenols | 上海工程技术大学 | 2018-06-29 | — | — | CN | claimed |
| WO-2017208253-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-12-07 | — | — | WO | claimed |
| US-9573902-B2 | Process for the preparation of Ivacaftor and its intermediates | LAURUS LABS PRIVATE LTD. (IN) | 2017-02-21 | — | — | US | claimed |
| US-20160280654-A1 | Solid Forms of Ivacaftor and Processes for the Preparation Thereof | THE BANK OF NOVA SCOTIA (CA) | 2016-09-29 | — | — | US | claimed |
| CN-105884628-A | Preparation method of 2,4-ditertbutyl-5-aminophenol | 上海工程技术大学 | 2016-08-24 | — | — | CN | claimed |
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS LIMITED (IN) | 2016-01-21 | — | — | US | claimed |
| WO-2015070336-A1 | SOLID FORMS OF IVACAFTOR AND PROCESSES FOR THE PREPARATION THEREOF | APOTEX INC. (CA) | 2015-05-21 | — | — | WO | claimed |
| WO-2014125506-A2 | A PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | LAURUS LABS PRIVATE LIMITED (IN) | 2014-08-21 | — | — | WO | claimed |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274081-B2 | Process for the synthesis of ivacaftor | IDO1, IDO2, SLC10A2 | ALDH1A1 172/4885ALOX15 951/4885SMN1; SMN2 4730/4885 |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | ALDH1A1 2977/4885ALOX15 3476/4885SMN1; SMN2 2820/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | ALDH1A1 2326/4885ALOX15 1451/4885SMN1; SMN2 4297/4885 |
| US-20200325104-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR | IDO1, SLC10A2, IDO2 | ALDH1A1 206/4885ALOX15 1148/4885SMN1; SMN2 4704/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885ALOX15 3245/4885SMN1; SMN2 4740/4885 |
| US-20160016909-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS INTERMEDIATES | SLC10A2, SLC26A4, SLC10A1 | ALDH1A1 687/4885ALOX15 3078/4885SMN1; SMN2 3782/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | ALDH1A1 1781/4885ALOX15 4717/4885SMN1; SMN2 1294/4885 |
| US-20160280654-A1 | Solid Forms of Ivacaftor and Processes for the Preparation Thereof | PCSK9, SLC10A1, VKORC1 | ALDH1A1 1390/4885ALOX15 1075/4885SMN1; SMN2 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.